Related references
Note: Only part of the references are listed.Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164
Dung T. Le et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer
T. Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome
Federico Innocenti et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC
Fabrice Barlesi et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Patient-reported outcomes and health-related quality of life for cetuximab versus bevacizumab in metastatic colorectal cancer: a prospective cohort study
Rui Pedro Marques et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)
Long-term neuropathy and quality of life in colorectal cancer patients treated with oxaliplatin containing adjuvant chemotherapy
L. M. Soveri et al.
ACTA ONCOLOGICA (2019)
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer
Michael J. Overman et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer
David J. Vaughn et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Improving Outcomes in Patients with CRC: The Role of Patient Reported Outcomes-An ESDO Report
Eric Van Cutsem et al.
CANCERS (2017)
Quality of Life Analysis in Patients With RAS Wild-Type Metastatic Colorectal Cancer Treated With First-Line Cetuximab Plus Chemotherapy
Kensei Yamaguchi et al.
CLINICAL COLORECTAL CANCER (2017)
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
E. Van Cutsem et al.
ANNALS OF ONCOLOGY (2016)
Methodological and Reporting Quality of Comparative Studies Evaluating Health-Related Quality of Life of Colorectal Cancer Patients and Controls: A Systematic Review
Carlos K. H. Wong et al.
DISEASES OF THE COLON & RECTUM (2016)
Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma
Dirk Schadendorf et al.
EUROPEAN JOURNAL OF CANCER (2016)
Role of targeted therapy in metastatic colorectal cancer
Yoshihito Ohhara et al.
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY (2016)
Quality of life during first-line FOLFOX4±panitumumab in RAS wild-type metastatic colorectal carcinoma: results from a randomised controlled trial
Salvatore Siena et al.
ESMO OPEN (2016)
Symptom Prevalence in Lung and Colorectal Cancer Patients
Anne M. Walling et al.
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT (2015)
Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies
Sabine Venderbosch et al.
CLINICAL CANCER RESEARCH (2014)
Quality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin
Istvan Lang et al.
EUROPEAN JOURNAL OF CANCER (2013)
Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30
K. Cocks et al.
EUROPEAN JOURNAL OF CANCER (2012)
Clinical and psychometric validation of the EORTC QLQ-CR29 questionnaire module to assess health-related quality of life in patients with colorectal cancer
R. N. Whistance et al.
EUROPEAN JOURNAL OF CANCER (2009)
Health-Related Quality of Life Impact of Bevacizumab When Combined with Irinotecan, 5-Fluorouracil, and Leucovorin or 5-Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Fairooz F. Kabbinavar et al.
ONCOLOGIST (2008)
Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer
A. Simon Pickard et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2007)
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.
LB Saltz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
A de Gramont et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
